Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

5.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The long run: A tribute to Arthur Joseph Lawrence Cooper.

Analytical biochemistry·2026
Same author

[3-<sup>11</sup>C]Pyruvate PET detects alterations in cardiac pyruvate metabolism induced by doxorubicin chemotherapy.

Npj imaging·2026
Same author

Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Aging differentially affects the uptake of methionine by select rat tissues.

Analytical biochemistry·2026
Same author

The Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for Prostate Cancer.

European urology·2026
Same author

FAP PET identifies earlycardiac molecular changesinduced by doxorubicin chemotherapy.

JCI insight·2025

Related Experiment Video

Updated: Sep 22, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

Advances in PSMA theranostics.

Thomas M Jeitner1, John W Babich2, James M Kelly3

  • 1Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, 413 East 69th Street, Room BB-1604, New York, NY 10021, USA.

Translational Oncology
|May 21, 2022
PubMed
Summary
This summary is machine-generated.

Prostate specific membrane antigen (PSMA) theranostics offers advanced imaging and targeted radiation delivery for metastatic prostate cancer. This review details current PSMA ligands and future directions for improved treatment efficacy.

Keywords:
PSMATargeted alpha therapyTargeted radioligand therapyTheranostics

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.9K

Related Experiment Videos

Last Updated: Sep 22, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.9K

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Prostate specific membrane antigen (PSMA) is validated as a key molecular target in metastatic castration-resistant prostate cancer.
  • Theranostic ligands targeting PSMA enable disease imaging and targeted delivery of cytotoxic radioactivity.
  • PSMA theranostics is increasingly integrated into clinical prostate cancer management.

Purpose of the Study:

  • To review the biological roles and activity of PSMA.
  • To highlight clinically advanced PSMA-targeting molecules and biomacromolecules.
  • To identify next-generation PSMA ligands for enhanced treatment efficacy.

Main Methods:

  • Comprehensive literature review of published research on PSMA theranostics.
  • Analysis of current PSMA targeting molecules and biomacromolecules.
  • Identification of emerging PSMA ligands and their potential applications.

Main Results:

  • PSMA theranostics is a rapidly advancing field with significant clinical impact.
  • Multiple classes of theranostic ligands targeting PSMA have been developed.
  • Next-generation ligands aim to improve targeting specificity and therapeutic outcomes.

Conclusions:

  • PSMA theranostics represents a significant advancement in prostate cancer management.
  • Continued development of PSMA ligands is crucial for improving treatment efficacy.
  • This review provides a roadmap for future progress in PSMA-based theranostics.